Aptus Pharma Ltd enters into Urology therapy segment

Aptus Pharma Limited has announced its strategic entry into the Urology therapy segment as part of its ongoing business expansion initiatives.

The Company will soon be launching a new portfolio of products in this segment, including:

- Silodosin range
- Tamsulosin range
- Alkalizer formulations

The introduction of these products is supported by the Company's strong field-sales force and a robust distribution network consisting of 150+ PLS distributors and sub-distributors across India. This new portfolio is expected to contribute significantly to the Company's future revenue growth and profitability.

The Indian urology market is one of the fastest-growing chronic therapy segments, currently expanding at approximately 9-10% annually.

Commenting on this development, Tejash Hathi, Managing Director, Aptus Pharma Limited., stated: "Our entry into the urology therapy segment further strengthens our specialty-care capabilities and positions the Company for sustained growth in the coming years."

Shares of Aptus Pharma Limited was last trading in BSE at Rs. 160.50 as compared to the previous close of Rs. 153.75. The total number of shares traded during the day was 6000 in over 3 trades.

The stock hit an intraday high of Rs. 160.50 and intraday low of 157.00. The net turnover during the day was Rs. 949000.00.

Source : Equity Bulls

Keywords

AptusPharma INE15XJ01010 Pharmaceuticals UrologyTherapy NewSegmentForay